Outcomes after CAR-T and radiation therapy for blood cancers
Outcomes After Chimeric Antigen Receptor Therapy (CAR-T) and Radiation Therapy (RT) for Hematologic Malignancies
This study looks at how combining CAR-T therapy with radiation treatment affects people with blood cancers to see if it can improve their outcomes and reduce side effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | CAR-T, radiation, chimeric antigen receptor |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT04888338 on ClinicalTrials.gov |
What this trial studies
This observational study collects data on patients with hematologic malignancies who are receiving chimeric antigen receptor therapy (CAR-T) and radiation therapy. It aims to record clinical outcomes, patient-specific factors, and treatment-related factors to improve patient selection and treatment strategies. By analyzing the relationship between radiation dose, technique, and timing with CAR-T therapy, the study seeks to optimize clinical outcomes and minimize treatment toxicity. Patient medical records and imaging data will be reviewed to assess disease progression and survival rates.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 years or older who are receiving or planning to receive CAR-T therapy and/or radiation therapy for hematologic malignancies.
Not a fit: Patients who are not undergoing CAR-T therapy or radiation therapy for hematologic malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment strategies for patients with hematologic malignancies, leading to improved outcomes.
How similar studies have performed: Other studies have shown promise in optimizing treatment strategies for hematologic malignancies using CAR-T and radiation therapy, indicating that this approach is supported by prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Treatment with or intention to treat with radiation therapy, standard-of-care CAR-T cell therapy and/or standard-of-care bispecific therapy, within a 90 day window for a hematologic malignancy
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Penny Q Fang — M.D. Anderson Cancer Center
- Study coordinator: Penny Q Fang, MD
- Email: pfang@mdanderson.org
- Phone: 713-563-2345
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.